MedTrace Logo

Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America

NCT01200160 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2014-06-06

Study results available
· View outcomes & findings →

Summary

Post-Marketing Observational study of Niaspan® tablet in accordance with each country regulations. This study will be conducted in a prospective, single-arm, multi-center format. As this study is observational in nature, the follow-up of subject's is not prescriptive in nature and is according to the judgment of the physician (investigator in the course of treatment for each patient), within the period of observation of 12 months. This includes an enrollment period of 6 months in which each subject will be observed for approximately 6 months. Examinations, diagnostic measures, findings and observations performed as per usual medical practice during the observation period will be recorded on Case Report Forms (CRFs) by the investigator or site staffs according to the protocol.

Conditions

Interventions

DRUG

Niacin

Sponsors & Collaborators

  • QUASY

    collaborator UNKNOWN

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Enrique C Morales Villegas, MD · Centro de Investigación Cardiometabólica

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Colombia
  • Mexico
  • Venezuela

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01200160 on ClinicalTrials.gov